Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01797185 · ClinicalTrials.gov registry record · Phase 3
Safety Study of SPARC1104
A Phase 3 study, sponsored by Sun Pharma Advanced Research Company Limited.
- Completed
- Registry status
- Phase 3
- Development phase
- 375
- Enrollment target
NCT01797185: Completed Phase 3 study, sponsored by Sun Pharma Advanced Research Company Limited.
NCT01797185 is a Phase 3 study that has completed, run by Sun Pharma Advanced Research Company Limited. The registered enrollment target is 375 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (51% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01797185, a Phase 3 study, has completed, sponsored by Sun Pharma Advanced Research Company Limited.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 375 participants
- Enrollment target
Study Summary
Open-label, safety study of SPARC1104 in subjects with spasticity due to multiple sclerosis
Interventions
- DRUG SPARC1104 modified dose regimen I
- DRUG SPARC1104 modified dose regimen II
- DRUG SPARC1104 modified dose regimen III
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 375 participants |
| Start Date | 2013-04-09 |
| Est. Completion | 2017-10 |
| Phase | Phase 3 |
What the finished NCT01797185 record still lists
NCT01797185 is an interventional study that assigns participants to a tested intervention. The registered 375 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (51% lower).
The record links to 0 conditions, and to 3 interventions - of which SPARC1104 modified dose regimen I is the first listed.
NCT01797185 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01797185 about?
NCT01797185 is a clinical study titled "Safety Study of SPARC1104". Open-label, safety study of SPARC1104 in subjects with spasticity due to multiple sclerosis
What is the current status of trial NCT01797185?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 375 participants. The study started on 2013-04-09. Estimated completion is 2017-10.
What interventions are being tested in trial NCT01797185?
The interventions under investigation include: SPARC1104 modified dose regimen I (DRUG), SPARC1104 modified dose regimen II (DRUG), SPARC1104 modified dose regimen III (DRUG).
Who is sponsoring clinical trial NCT01797185?
This trial is sponsored by Sun Pharma Advanced Research Company Limited, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01797185's enrollment target sits among peer trials
375 988th of 2000 higher than 1,010 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03686124 · 375 participants · Phase 1
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- NCT04059172 · 375 participants · Early Phase 1
Efficacy of Combined Ibuprofen and Acetaminophen Therapy Versus Ibuprofen Alone Versus Placebo Alone for Pain Management
- NCT04134923 · 375 participants
Imaging Biomarkers in Preclinical and Symptomatic AD
- NCT04569747 · 375 participants · Phase 2
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI